ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.
In the cellular process of differentiation, information about the concentrations of an important class of proteins residing in a cell’s nucleus has been lacking, a missing link needed for scientists to fully understand how the process works. ISB researchers have quantified this important class of proteins that play a key role in the formation of red blood cells.
The National Institutes of Health announced the launch of a new Alzheimer’s Big Data portal, which includes the first wave of data for use by the research community. This portal is the result of the Accelerating Medicines Partnership (AMP) program, which focuses on facilitating collaboration among government agencies, academia and industry in order to translate research more quickly to therapies. The launch of the AMP Alzeheimers Disease Knowledge Portal is…
Cover of the November 2014 issue of Real Simple Magazine A team at ISB has been working on the 100K Wellness Project, which you read about here. The November issue of Real Simple Magazine has a feature story on “What Exactly is Wellness?” It includes a mention of our wellness study and a comment from Dr. Nathan Price, ISB associate director. “Perhaps one reason why wellness programs aren’t yet commonplace…
Nathan Price and Vangelis Simeonidis, a visiting scholar from Luxembourg Centre for Systems Biomedicine (LCSB is a major strategic partner with ISB), contributed to this paper – “A community-driven global reconstruction of human metabolism” – that was published today in Nature Biotechnology. An excerpt describing the collaborative project from a press release is below. An interactive map is forthcoming. From Medicalxpress.com: “An international consortium of university researchers has produced…